Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 625-633

  Walzer, Peter D ^a,d,e   Evans, Hannah E R ^b   Copas, Andrew J ^b   Edwards, Simon G ^c   Grant, Alison D ^a   Miller, Robert F ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Camden Primary Care Trust   (United Kingdom)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATOVAQUONE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; HEMOGLOBIN; MALOPRIM; OXYGEN; PENTAMIDINE; PRIMAQUINE; TRIMETHOPRIM;

ADULT; AGE; AGED; AMBIENT AIR; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FATALITY; FEMALE; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTION; OXYGEN BREATHING; OXYGEN TENSION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ISOLATION AND PURIFICATION; MIDDLE AGED; UNITED KINGDOM;

ADULT; AGED; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LONDON; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS;

EID: 38849180490     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526778     Document Type: Article

References (41)

1. Redhead SA, Cushion MT, Frenkel JK, Stringer JR. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 2006; 53:2-11.
2. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350:2487-98.
3. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10:1713-20.
4. Pulvirenti J, Herrera P, Venkataraman P. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS 2003; 17:261-5.
5. Colford JM, Segal M, Tabnak F, Chen M, Sun R, Tager I. Temporal trends and factors associated with survival after Pneumocystis carinii pneumonia in California, 1983-1992. Am J Epidemiol 1997; 146:115-27.
6. Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis 2001; 183:1409-12.
7. Lundgren JD, Barton SE, Katalama C, et al. Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in Europe. Arch Intern Med 1995; 155:822-8.
8. Benfield TL, Helweg-Larsen J, Bang D, Junge J, Lundgren JD. Prognostic markers of short-term mortality in AIDS- associated Pneumocystis carinii pneumonia. Chest 2001; 119:844-51.
9. Kim B, Lyons TM, Parada JP, et al. HIV-related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAART era. J Gen Intern Med 2001; 16:583-9.
10. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. cariinii pneumonia. Lancet 1999; 354:1347-51.
11. Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1987; 147:1413-7.
12. Brenner M, Ognibene FP, Lack E, et al. Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis 1987; 136:1199-206.
13. Benson CA, Spear J, Hines D, Pottage JC, Kessler HA, Trenholme GM. Combined APACHE II score and serum lactate dehydrogenase as predictors of in-hospital mortality caused by first episode Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Am Rev Respir Dis 1991; 144:319-23.
14. Bauer T, Ewig S, Hasper E, Rockstroh JK, Luderitz B. Predicting in-hospital outcome in HIV-associated Pneumocystis carinii pneumonia. Infection 1995; 23:272-7.
15. Forrest DM, Zala C, Djurdjev O, et al. Determinants of short- and long-term outcome in patients with respiratory failure caused by AIDS-related Pneumocystis carinii pneumonia. Arch Intern Med 1999; 159:741-7.
16. Mason GR, Hashimoto CH, Dickman PS, Foutty LF, Cobb CJ. Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis 1989; 139:1336-42.
17. Bang D, Emborg J, Elkjaer J, Lundgren JD, Benfield TL. Independent risk of mechanical ventilation of AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia. Respir Med 2001; 95:661-5.
18. Beck EJ, Mandalia S, Miller DL, Harris JR. Hospital service interventions and improving survival of AIDS patients at St Mary's Hospital, London, 1982-1991. Int J STD AIDS 1998; 9:280-90.
19. Ahmad H, Mehta NJ, Manikal VM, et al. Pneumocystis carinii pneumonia in pregnancy. Chest 2001; 120:666-71.
20. Fernandez P, Torres A, Miro JM, et al. Prognostic factors influencing the outcome in Pneumocystis carinii pneumonia in patients with AIDS. Thorax 1995; 50:668-71.
21. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
22. Miller RF, Allen E, Copas A, Singer M, Edwards SG. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006; 61:716-21.
23. Miller RF, Tomlinson MC, Cottrill CP, Donald JJ, Spittle MF, Semple SJ. Bronchopulmonary Kaposi's sarcoma in patients with AIDS. Thorax 1992; 47:721-5.
24. Miller RF, Millar AB, Weller IV, Semple SG. Empirical therapy without bronchoscopy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Thorax 1989; 44:559-64.
25. Wakefield AE, Lindley AL, Ambrose HE, Denis CM, Miller RF. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187:901-8.
26. Miller RF, Evans HER, Copas AJ, Cassell JA. Climate and genotypes of Pneumocystis jirovecii. Clin Microbiol Infect 2007; 13:445-8.
27. Shafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8:3-15.
28. A complex picture - HIV and other sexually transmitted infections in the United Kingdom: 2006. The UK Collaborative Group for HIV and STI Surveillance, Health Protection Agency, London. Available at: http://www.hpa.org.uk/ publications/2006/hiv_sti_2006/contents.htm. Accessed 6 October 2007.
29. Arozullah AM, Yarnold PR, Weinstein RA, et al. A new preadmission staging system for predicting inpatients mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era. Am J Resp Crit Care Med 2000; 161:1081-6.
30. Uphold CR, Deloria-Knoll M, Palella FJ, et al. US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. Chest 2004; 125:548-56.
31. Curtis JR, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Resp Crit Care Med 2000; 162:393-8.
32. Morris A, Creasman J, Turner J, Luce J, Wachter RM, Huang L. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Resp Crit Care Med 2002; 166:262-7.
33. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated causes to other immunosuppressed states. Chest 2000; 118: 704-11.
34. Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Arch Intern Med 1992; 152:2465-70.
35. Morris AM, Huang L, Bacchetti P, et al. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med 2000; 162:612-8.
36. Diaz PT, King MA, Pacht ER, et al. The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999; 160:272-7.
37. Daly K, Huang L, Morris A, et al. Antibody response to the Pneumocystis jirovecii major surface glycoprotein. Emerg Infect Dis 2006; 12:1231-7.
38. Mitchell DM, McCarty M, Fleming J, Moss FM. Bronchopulmonary Kaposi's sarcoma in patients with AIDS. Thorax 1992; 47:726-9.
39. Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003; 58:594-7.
40. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004; 170:408-13.
41. Horner RD, Bennett CL, Rodriguez D, et al. Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Resp Crit Care Med 1995; 152:1435-42.